DNA-based vaccines hold promise to outperform conventional antigen-based vaccines by virtue of many unique features. However, DNA vaccines have thus far fallen short of expectations, due in part to poor targeting of professional antigen-presenting cells (APC) and low immunogenicity. In this study, we describe a new platform for effective and selective delivery of DNA to APCs in vivo that offers intrinsic immuneenhancing characteristics. This platform is based on conjugation of fifth generation polyamidoamine (G5-PAMAM) dendrimers, a DNA-loading surface, with MHC class II-targeting peptides that can selectively deliver these dendrimers to APCs under conditions that enhance their immune stimulatory potency. DNA conjugated with this platform efficiently transfected murine and human APCs in vitro. Subcutaneous administration of DNA-peptide-dendrimer complexes in vivo preferentially transfected dendritic cells (DC) in the draining lymph nodes, promoted generation of high affinity T cells, and elicited rejection of established tumors. Taken together, our findings show how PAMAM dendrimer complexes can be used for high transfection efficiency and effective targeting of APCs in vivo, conferring properties essential to generate effective DNA vaccines. Cancer Res; 71(24); 7452-62. Ó2011 AACR.
Introduction
The use of naked plasmid DNA as a vaccine to prime the immune system provides a variety of practical benefits for large-scale production that are not as easily achievable with other forms of vaccines including recombinant proteins or whole tumor cells (1) (2) (3) (4) . While numerous clinical trials have proven the safety of this cost effective vaccination strategy, they have also revealed its limitations, as the immune response elicited is insufficient to clear established tumors or infections. The low in vivo transfection efficiency, the absence of preferential targeting of professional antigen-presenting cells (APC), and the modest intrinsic adjuvant activity of DNA vaccines are thought to be the main reasons for the marginal effect observed in clinical studies and in therapeutic murine models. An accepted assumption is that the immunogenic potency of DNA-based vaccines can be significantly increased if the delivery of DNA to professional APCs is maximized and if additional immunologic help in the form of adjuvants and/ or cytokines is provided (5, 6) .
We present here a new platform for DNA delivery that fulfills these characteristics. This platform is based on the use of generation 5 polyamidoamine (G5-PAMAM) dendrimers conjugated with MHC class II-targeting peptides.
Although PAMAM dendrimers have been tried as vaccine platform as their positive charge allows the complexation at physiologic pH of DNA protecting it from nuclease and increasing the transfection efficiency (7, 8) , in vivo, they showed only modest success. A marginally significant increase in vaccine efficacy was obtained also with universal peptides used as adjuvant, although a large number of helper T cells were activated by these molecules (9) . In contrast, the conjugation of PAMAM dendrimer and universal peptides not only combines their positive properties but allows a highly selective delivery of DNA to APCs which dramatically increases the efficacy of DNA vaccines ( Supplementary  Fig. S1 ).
Materials and Methods
Cell lines and culturing conditions B16F10 (ATTC) is a C57BL/6 melanoma cell line. B16 melanoma cells (H2 b ) stably expressing chicken OVA (B16OVA.pc) were provided by Dr. G. Barber (University of Miami, Miami, FL). MBL2, a lymphoma cell line derived from C57BL/6 mice; CT26, a BALB/c-derived colon carcinoma; and TSA, a BALB/c-derived mammary tumor adenocarcinoma were kindly supplied by Dr. V. Bronte (University of Verona, Verona, Italy). Cell lines were cultured in complete medium [RPMI-1640 media (Invitrogen) supplemented with 2 mmol/L L-glutamine, 10 mmol/L HEPES, 20 mmol/L 2-mercaptoethanol, 150 m/mL streptomycin, 200 m/mL penicillin, and 10% heat-inactivated FBS (Invitrogen)]. B cells from ficolled peripheral blood mononuclear cells (PBMC) were isolated by negative selection using anti-biotin microbeads (Miltenyi Biotech) after staining with a biotinylated anti-CD3 antibody (BD Biosciences), according to the MiniMacs protocol (Miltenyi Biotech). After purification, B cells (10 6 per mL) were cultured overnight in complete medium supplemented with 5 mg/mL CpG (ODN 2006; Invivogen). Human dendritic cells (DC) were differentiated from monocytes isolated from ficolled PBMCs with granulocyte-macrophage colony-stimulating factor (GM-CSF; 10 ng/mL) and interleukin 4 (IL-4; 10 ng/mL) for 5 days. Maturation was induced by adding the mimic maturation cocktail [TNFa (5 ng/mL), IL-1b (5 ng/mL), IL-6 (75 ng/mL), and prostaglandin E2 (PGE2; 1 mg/mL)]. Experiments were carried out using PBMCs isolated from healthy adult volunteers after appropriate signed consent and Institutional Review Board approval.
ELISA
Mixed lymphocyte peptide cultures (MLPC) were carried out by culturing 25 x 10 6 red blood cells (RBC)-lysed splenocytes with 10 mL of 1 mmol/L peptide for 5 days at 37 C 5% CO 2 in a 25 mL flask (BD Biosciences). A total of 10 5 MLPCs derived T cells were restimulated for 24 hours with an equal amount of target cells; the supernatants were harvested and tested for the IFN-g released in a sandwich ELISA (Endogen) following manufacturer's instructions.
Flow cytometry
The detailed protocol for cell staining and the list of the antibodies used is described in the Supplementary Material.
Fluorophore-linked immunosorbent assay (FLISA) was conducted as previously described (10) and further described in the Supplementary Material.
Peptides and plasmids
pcDNA3 (Invitrogen), pcDNA3-tyrosine-related protein-2 (TRP2) and pcDNA3-gp70 were previously described (11, 12) . pcDNA3-ovalbumin (pcDNA3-OVA) was a gift from Dr. Barber (University of Miami, Miami, FL) and pMAX-GFP were obtained from Lonza. All plasmids were prepared by the endotoxin-free Gigaprep Kit (Invitrogen). The following peptides were used: gp70-derived AH1, SPSYVYHQF (AnaSpec); TRP2 [180] [181] [182] [183] [184] [185] [186] [187] [188] Conjugation of the peptides to the dendrimers Peptide-dendrimer conjugates were manufactured by crosslinking 5th generation dendrimer (Dendritech) and peptides target as follows: PADRE and HA 110-120 with an added cysteine at the c-terminus with maleimido-bis-succinimidyl ester (MBS; Sigma-Aldrich) as reported in the Supplementary Material.
DNA-nanoparticle complexation
DNA (100 mg/mL) was resuspended in warm (37 o C) PBS (pH 7.4; Invitrogen) for scanning electron microscopy (SEM) and ethidium bromide (EtBr) exclusion assay or Opti-MEM (Invitrogen) for DNA vaccine and in vitro transfection. DNA solution was added drop wise to the nanoparticles with a p100 tip to an equal volume of DNA versus nanoparticles while the vial containing nanoparticle was being vortexed. Amine:phosphate (N:P) ratio 10:1 was used unless otherwise indicated.
EtBr exclusion assay
A total of 100 mL of DNA (50 mg/mL) were admixed in a 96-well plate with different amounts of nanoparticle and incubated for 5 minutes at room temperature. EtBr was added (400 ng/mL), fluorescence determined on a VERSA doc 3000 (Biorad) and images analyzed by ImageJ (http://rsbweb.nih. gov/ij/). Data from duplicate wells are reported as percentage of free DNA using the formula: % free DNA ¼ (FI) experimental / (FI) control Â 100.
Mice and vaccination
Eight-week-old C57BL/6 (H2 b ) and BALB/c (H2 d ) mice were purchased from Harlan. Procedures involving animals and their care conformed to institutional guidelines that comply with national and international laws and policies and were approved by the University of Miami IACUC. In experiments with tumors, mice were ear tagged, randomized after treatment, and tumor growth was monitored 3 times a week with a caliper by an investigator blinded to the treatment. Mice were euthanized when the tumor size index (the product of 2 perpendicular diameters) was bigger than 100 mm 2 . Vaccination with the DNA-nanoparticle complexes was carried out by subcutaneous injection of 200 mL of DNA-nanoparticle complexes at an N:P ratio ¼ 10:1 in Opti-MEM (Invitrogen). Dermal electroporation (13) was carried out with DermaVax (Cellectis-Bioscience Inc.) following manufacturer's instruction and further detailed in the Supplementary Methods.
Statistical analysis
SigmaPlot (Systat Software Inc.) was used for statistical analysis. One-way ANOVA was conducted after normality evaluation by Kolmogorov-Smirnov test. Pairwise posthoc analysis was conducted using the Holm-Sidak test or the Dunn test. ANOVA on ranks was used if the sample were not normally distributed. The Student t test was used when 2 groups needed to be compared. Kaplan-Meier log-rank followed by the HolmSidak posthoc analysis was used to evaluate the survival differences between groups.
SEM
B cells were fixed (24 hours in 4% gluteraldehyde in 0.1 mol/L PBS buffer at 4 o C), rinsed 3 times in PBS, and postfixed in 1% osmium tetroxide for 20 minutes. Cells were dehydrated in a graded series of ethanol, rinsed with hexamethyldisilazane, placed on bare aluminium stubs (12-mm diameter), and outgas overnight. The samples were sputter coated with palladium in a Cressington-108 Auto Sputter Coater and imaged in a Phillips XL-30/ESEM-FEG (15-30 kV).
Results

Synthesis and characterization of peptide-conjugated PAMAM dendrimer
To target the dendrimer to the APCs, we used the following 2 MHC class II-restricted peptides: (i) the influenza hemoagglutinin-derived H2-I-E d -restricted HA 110-120 peptide and (ii) PADRE which has high affinity for more than 95% of all human leukocyte antigen-D related (HLA-DR) and for the murine H2-I-A b (9, (14) (15) (16) Fig. S2 ) determined that 8 mol/L excess concentrations of MBS for derivatizing the dendrimers followed by a 4 mol/L excess of purified peptide were the optimal conditions as determined by reversed-phase high-pressure liquid chromatography (RP-HPLC) and mass spectrometry (Supplementary Fig. S3 ).
Reaction products [PADRE-conjugated PAMAM Dendrimer (PPD) and HA-conjugated PAMAM Dendrimer (HAPD)] were purified by HPLC ( Supplementary Fig. S3A and S3B) resulting in an essentially pure material with negligible contamination by either free dendrimer or peptides.
Effective conjugation of the peptide to the dendrimer was indicated by proton nuclear magnetic resonance ( 1 H-NMR) spectroscopy (Fig. 1A) and confirmed by UV-visible spectroscopy ( Fig. 1B and Supplementary Fig. 3C ). The average mass of the purified peptide-nanoparticle ( the target cells; however, the size and biological properties of the DNA-nanoparticle complexes are dependent on the ratio between the positively charged amine (N) in the dendrimer and the negatively charged phosphate (P) in the DNA. EtBr exclusion assay (Fig. 1D ) determined that at an N:P ratio of 10:1 more than 90% of the DNA was complexed with the dendrimer. No macroscopic precipitates were visible at 40Â magnification with optical microscopy (data not shown). DNA-peptide-dendrimer complexes generated at different N:P ratios were further characterized by SEM. At a 1:1 N:P ratio the formation of filament-shaped particles (Fig. 1E ) suggested incomplete complex formation. Globular particles with a diameter of approximately 200 and 600 nm were generated when 5:1 and 10:1 ratios were used. At higher N:P ratios, macroprecipitates were generated ( Fig. 1F and Supplementary Fig. S4 ). These data indicate that it is possible to conjugate peptides to the dendrimers without affecting their capacity to bind and complex DNA. However, we observed that variations of the N:P ratio resulted in the generation of complexes of different sizes and shapes, highlighting that this is an important variable that must be accounted for when analyzing the outcomes of the transfection experiments.
Dendrimers conjugated with MHC class II-binding peptides preferentially target APCs in vitro and in vivo
To verify whether PPD or HAPD are efficient in targeting APCs and determine the N:P ratio with the optimal transfection efficiency, pMAX-GFP was complexed with the PPD nanoparticle or with unconjugated dendrimers at different N:P ratios and used to transfect magnetically purified human B cells ( Fig.  2A and B) or monocytic-derived human DC (Fig. 2C) . fluorescence-activated cell-sorting (FACS) analysis conducted 48 hours after transfection with PPD-GFP revealed that GFP expression was maximal at a 10:1 N:P ratio ( Fig. 2A ) by either mean fluorescence intensity (MFI) or percentage of transfected cells (Fig. 2B) , whereas the transfection efficiency of the unconjugated dendrimer was inferior at the same N:P ratio. Similar data were obtained using PPD on C57BL/6 splenocytes or HAPD-GFP on BALB/c splenocytes (data not shown) or when human DCs were used ( Fig. 2C ), suggesting that, while complex size can play an important role in PPD ability to transfect the target cells, it minimally influences its specificity. Interestingly, PPD-mediated transfection of immature DC induced the upregulation of CD40, but not CD80, even in the absence of maturation cocktail (mimic, Fig. 2D ). To further evaluate the specificity of the DNA-PPD complexes, . C, human DC were differentiated from monocytes precursors using GM-CSF and IL-4 for 5 days and GFP transfected using PPD or dendrimer at the indicated N:P ratio. Maturation cocktail (mimic) was added 2 hours after the transfection, and GFP intensity was evaluated 24 hours later. D, immature human DC prepared as in (C) were transfected with pcDNA. Maturation cocktail (mimic) was added where indicated, and expression of CD40 and CD80 was evaluated 24 hours later. unconjugated dendrimer or PPD loaded with pcDNA3 were incubated for 20 minutes at room temperature with magnetically purified human B cells. Cells were then washed, fixed, and imaged in the SEM (Supplementary Fig. S1B ). Whereas particles with a size similar to the DNA-PPD complexes were found on the membrane of B cells treated with PPD (Supplementary Fig. S1B ), similar structures were undetectable in the B cells treated with unconjugated dendrimer. These data indicate that N:P ratio ¼ 10:1 results in maximum transfection and that the addition of MHC class II-binding peptide increases the in vitro transfection efficiency of the dendrimer in APCs.
To evaluate the efficiency and specificity of these platforms in vivo, PPD or HAPD dendrimers complexed with pMAX-GFP (PPD-GFP and HAPD-GFP) were injected subcutaneously into C57BL/6 or BALB/c mice, and draining lymph nodes were harvested and analyzed 48 hours later. Controls included mice injected with PBS or with a pMAX-GFP-loaded unconjugated dendrimer. Whereas only basal fluorescence was found in the contralateral lymph nodes, FACS analysis revealed a higher number of GFP þ , MHC class II þ cells in the draining lymph node of mice treated with PPD ( Fig. 3A) , indicating a preferential in vivo targeting of APCs. These GFP þ cells were mostly mature DC as revealed by the expression of H2-I-A b , CD11c, CD80, and CD86 (Fig. 3B) . A total of 50% of the transfected DC were CD11b high CD103 low/neg CD8 low/neg , 30% CD11b low CD8 low/neg CD103 low/neg DC, the remaining were CD11b low and positive for CD8 and/or CD103 (Fig. 3B) . Similar ratios were found in the untransfected DC from the contralateral lymph node, suggesting the absence of a preferential targeting for any of the examined DC subsets. Interestingly, the absolute number of DC was also elevated (Fig. 3C  and D) in the PPD group, confirming the immunostimulatory properties of this peptide (14) . Conversely, mice treated with unconjugated dendrimer showed only marginal GFP fluorescence increase in the draining lymph nodes (Fig. 3A) and fewer GFP þ DC (Fig. 3C) . Results similar to those seen with PADRE were obtained using the HAPD platform in BALB/c mice (Fig. 3D) . To determine whether the higher transfection specificity of the PPD platform in vivo results in effective immunization in mice, we used the weak, self melanocyte differentiation antigen TRP2. TRP2 is the main antigenic target of the immune response elicited in mice by immunization with genetically modified B16 melanoma vaccines (17, 18) . The anti-TRP2 immune response is dominated by CD8 þ T cells that can either have high avidity and elicit protection upon B16 challenge or have low avidity and fail to protect (18) . Whereas both high and low avidity clones can recognize TRP2 pulsed on MBL2 cell line, only high avidity clones can recognize unpulsed B16 cells (18) . C57BL/6 mice were immunized with pcDNA3-TRP2 or pcDNA3 using PPD or unconjugated dendrimers. Seven days later, mice were sacrificed and splenocytes stimulated with the relevant or irrelevant peptide. The cultures were then harvested, washed, and cultured for 24 hours with B16 cells or with MBL2 cells pulsed with TRP2 or with an irrelevant peptide. IFN-g ELISA was used as read out for CTLs activation. T cells isolated from mice immunized with either dendrimer-TRP2 or PPD-TRP2 can recognize TRP2-pulsed MBL2 (Fig. 4A) ; however, IFN-g secretion from the PPD group is 10 times higher than that seen with the control dendrimer. Conversely, only T cells from the group immunized with PPD-TRP2 recognize the antigen endogenously expressed by the B16 melanoma. Moreover, memory CTLs can be generated by the PPD platform as revealed by the experiments shown in Fig.  4B , in which the immune response in mice vaccinated twice (at day 0 and 7) with PPD-TRP2 or DR-TRP2 was measured at day 40. These data suggest that the conjugation of PADRE peptide to dendrimers enhances the immune response obtained by the dendrimer, generating high affinity memory T cells capable of recognizing not only TRP2-pulsed MBL2 but also the rare MHC class I molecules endogenously loaded with TRP2 in the B16 melanoma (12) . Similar data were obtained when HAPD was used in conjunction with the natural occurring tumor-associated gp70 antigen derived from the envelope protein of a murine endogenous retrovirus (19) : whereas T cells from both HAPD-gp70 and DR-gp70 can recognize APCs pulsed with the immunodominant gp70-derived AH1 peptide, only T cells from mice vaccinated with the HAPD particle were able to recognize the gp70 þ CT26 tumor (Fig. 4C ).
Peptide-conjugated dendrimers not only generate high affinity CTLs but also a humoral response. FLISA analysis (Fig.  4D) reveals that a single vaccination with pcDNA3-OVA results in high anti-OVA antibody titers in all vaccinated mice when PPD is used, whereas only modest results were obtained when unconjugated dendrimers or when dermal electroporation were used (Fig. 4D) . Similar results were obtained using 3 additional antigens in conjunction with PPD (data not shown). When electroporation or HAPD were used to vaccinate BALB/c mice using pcDNA3 encoding the viral G protein-coupled receptor (vGPCR), inferior results were obtained even when vaccination was conducted twice (Fig. 4E) : whereas electroporation generated high antibody titer in all mice analyzed, HAPD led to the generation of a good humoral response only in 4 of 8 of the mice (Fig. 4E) . These data indicate the capacity of PPD and HAPD to generate a humoral response and the generation of high affinity memory CTL with high affinity for the relevant antigen.
PPD is more effective than electroporation in promoting antitumor immunity
To compare the immunity induced by the PPD and HAPD platforms to that induced by dermal electroporation, today's gold standard for DNA vaccination, we used 2 tumor mouse models (B16OVA and CT26) in which electroporation has been shown to result in long-term survival of approximately 30% to 40% of the vaccinated mice (Fig. 5) . Whereas all mice vaccinated with pcDNA3 developed and succumb to the B16OVA tumor by day 28, prophylactic electroporation with pcDNA3-OVA resulted in a significant reduction of tumor appearance and growth, with a 20% survival rate of the mice. When OVA immunization was carried out with PPD, approximately 75% of the mice exhibited no tumor growth, showing a better therapeutic efficacy than the one obtained with electroporation (P ¼ 0.001, Fig. 5A ). Different results were obtained in the CT26 model using HAPD to immunize BALB/c against gp70. Whereas prophylactic electroporation with pcDNA3-gp70 resulted in the survival of 40% of mice challenged with CT26, gp70 immunization with HAPD allowed only 10% of the animals to survive, even if the delay in tumor formation seen in the group vaccinated with gp70 reached statistical significance (Fig. 5B) . Indeed, while electroporation and PADRE peptide should provide a "danger signal" that can promote the generation of strong immunity (14, 20) , this may not occur when the HA helper peptide, a nonuniversal T helper epitope, is used (21) . In additional experiments, in which we tested the immunogenicity of PPD in an immune-privileged site such the eye (22) , a single intracorneal immunization with 2 mg of PPD-GFP was sufficient to induce an elevated anti-GFP humoral response ( Supplementary Fig. S5 ). No anti-GFP antibodies were detected when unmodified dendrimers were used, further elucidating the strong adjuvant effect associated with the use of PPD.
PPD-mediated TRP2 vaccination leads to the rejection of established melanoma
If targeting DNA vaccine to MHC class II þ APC is important in a prevention setting, in a therapeutic model where tolerogenic mechanisms are elicited and the tumor is established, delivering the antigen to the professional APC might become the key for successful therapy (23) . PPD nanoparticles were therefore tested in the stringent therapeutic murine tumor melanoma model B16 (Fig. 6) . As mentioned earlier, the B16 tumor-associated antigen TRP2 is a weak antigen and only modest results are obtained when TRP2 is used to treat established melanomas (24) unless the antigen vaccination is carried out using powerful recombinant vaccinia virus (18) or combinatorial treatment (24, 25) . Coherent with previous results, immunization against TRP2, conducted 2 and 9 days after tumor injection using peptide unconjugated, control dendrimers, failed to induce protection (Fig. 6A) . However, when the same complexes were mixed with PADRE (DR-TRP2 þ PADRE) a modest, although statistically significant (P ¼ 0.045), increment of survival was observed compared with the empty vector-vaccinated mice (Fig. 6A) . Because in this case PADRE was not conjugated but only mixed with the dendrimer, this effect can be attributed to the adjuvant effect of PADRE. When vaccination against TRP2 was carried out with PPD (Fig. 6B , PPD-TRP2 group) a statistical and clinically significant prolongation of survival was observed with 50% of mice remaining tumor free (PPD-TRP2 vs. PPD-pcDNA3: P < 0.005) for the duration of the experiment (up to 350 days). These data indicate that PADRE needs to be linked to the dendrimer to promote a strong therapeutic effect, suggesting that both the specific targeting to the professional APCs and the adjuvant effect provided by the universal peptide are likely to be needed for a successful vaccination.
Regulatory T-cell depletion increases the therapeutic antitumor efficacy of HAPD-mediated gp70 vaccination
To test the HAPD platform, the gp70 þ TSA mammary adenocarcinoma model was used. When the cell line is injected into BALB/c mice, this results in moderately differentiated, poorly immunogenic, invasive tumors (26) . Although AH1-specific CTL can recognize this tumor in vitro, gp70 DNA immunization does not provide protection (12, 27) . Whereas HAPD-pcDNA3-gp70 (n = 10) Dendrimer-pcDNA3-gp70 (n = 10)
Electroporation-pcDNA3-gp70 (n = 5) Figure 5 . A, A total of 5 Â 10 4 B16OVA cells were injected on day 0 in C57BL/6 mice previously vaccinated (at day À10 and À25 days) with 20 mg of pcDNA3-OVA. Immunizations were conducted using electroporation (black square), or by subcutaneous injection of PPD particle (dotted gray circle), or unmodified dendrimer (gray triangle). As control, an additional group of mice was vaccinated using PPD loaded with pcDNA3 (black circle). Data are derived from 3 independent experiments. Log-rank P < 0.001, Holm-Sidak: PPD-OVA versus PPD-pcDNA3 or DR-OVA P < 0.00001; PPD-OVA versus EP P < 0.001; EP versus PPD-pcDNA3 P ¼ 0.02. B, BALB/c mice, vaccinated at day À15 and À8 with pcDNA3gp70 (20 mg), were challenged with 5 Â 10 4 CT26 cells at day 0. Immunization was conducted using dermal electroporation (black square), HAPD nanoparticle (gray-dotted circle), or control DR (gray triangle) subcutaneously. As an additional control, a group of mice was vaccinated with HAPD loaded with pcDNA3 (black circle). Data are derived from 2 independent experiments. Log-rank P < 0.001, Holm-Sidak: HAPD-gp70 versus HAPD-pcDNA3 P < 0.001; EP versus HAPD-pcDNA3 P < 0.001. Figure 6 . PPD promotes the rejection of established B16 melanoma tumors. C57BL/6 mice were injected subcutaneously on the right flank with the B16F10 tumor on day 0. On day 2 and 9, mice received as vaccine pcDNA3-TRP2 (gray square) or pcDNA3 (as control, black triangle) subcutaneously distributed in 4 anatomic sites (10 mg/site). Immunization was conducted using either unmodified DR (A) or PPD with (B). As additional controls, mice received PBS (white circle) or unmodified dendrimer loaded with pcDNA3-TRP2 and mixed with the same dose of PADRE peptide theoretically linked to the PPD (DR-TRP2 þ PADRE; gray diamond). Log-rank P < 0.001, Holm-Sidak: PPD-TRP2 versus PPD-pcDNA3,`P ¼ 0.001; PPD-TRP2 versus DR-TRP2 þ PADRE, P ¼ 0.03; DR-TRP2 þ PADRE versus no vaccine, P ¼ 0.04. C, tumor growth for the DR-TRP2 or the PPD-TRP2 group. 
Discussion
Although early data from clinical trials with DNA vaccines delivered by in vivo electroporation which greatly enhances the in vivo transfection efficiency are cautiously promising (29) , it is thought that the real promise of DNA vaccines can only be fulfilled when efficient in vivo targeting of professional APCs is combined with the proper adjuvant (5). TSA cells on day 0 received, on day 1 and 7, 40 mg of pcDNA3-GP70 subcutaneously divided in 4 different sites. Immunization was conducted using unmodified dendrimer (DR-gp70, gray square, top) or HAPD (HAPD-gp70, gray square, bottom). As control, mice received pcDNA3 (black triangle) or PBS (white circle). An additional group of mice receive a mixture of DR-gp70 and HA peptide (gray diamond). Log-rank P ¼ 0.011, Holm-Sidak: HAPD-gp70 versus HAPD-pcDNA3, P < 0.001. B, half of the mice in each group were intraperitoneally injected with isotype control (A) or with the anti-CD25 depleting antibody PC61 (100 mg) on day À1, 5, 12, and 21 (B). Untreated and unvaccinated mice were used as an additional control (white circle). Log-rank P < 0.001, Holm-Sidak: HAPD-pcDNA3 þ pc61 versus HAPD-gp70 þ pc61, P < 0.001; HAPD-gp70 versus HAPDgp70 þ pc61, P ¼ 0.007. C, tumor growth for the HAPD-gp70, pc61 group, or the combined treatment.
Here, we present a platform that fulfils the above criteria: it provides high transfection efficiency, proper targeting to the APCs, and an adjuvant effect. The platform is based on the synthesis, in a unique nanoparticle, of 2 technologies already independently tested with modest results: PADRE and PAMAM dendrimer.
The universal peptide PADRE binds/activates cells bearing any of the 15 major forms of the HLA-DR and has been widely used as immune adjuvant (14, 30, 31) . Its adjuvant (although modest) effect has been confirmed in this report (Fig. 6A) . In fact, coinjection of PADRE with unconjugated dendrimer loaded with TRP2-encoding plasmid marginally increased the efficacy of the vaccine. PAMAM dendrimers, because of their properties of DNA complexation and the capacity to be attached to the cell membrane, have been independently used as a platform for DNA vaccination (32) although only modest results were reported. Our data confirmed the capacity of unconjugated dendrimers to promote both humoral and cell-mediated immunity. Indeed, 4 of 5 mice immunized by unconjugated dendrimer show low affinity CTLs toward the antigen with which they were immunized (Fig. 4) . This low immunity, however, is not sufficient to protect mice from the subsequent challenge with B16OVA or CT26 (Fig. 5) nor it is effective in therapeutic models (Figs. 6 and 7) .
In striking contrast, the physical conjugation of the PAMAM dendrimer to the MHC class II-targeting peptide, dramatically increases the immunogenicity of the platform and the efficacy of DNA vaccines, overcoming the limitations of the current platform for DNA vaccination.
Both platforms presented here are able to preferentially deliver DNA to lymph nodal APCs where a selective transfection of DCs is observed (Fig. 3) . This preferential transfection of professional APCs results in the induction of high affinity CTLs and of humoral response to the antigen delivered (Fig. 4) . Interestingly, whereas PPD induces the appearance of a high number of transfected DC, a more limited number is found when HAPD is used (Fig. 3) . Consistently IFN-g secretion by CTLs in response to stimulation with the relevant tumor is lower when HAPD is used (Fig. 4) . Although we cannot exclude that the reason for these different responses lies in the tumor/ antigen used (TRP2 or AH1) or in intrinsic strain differences (C57BL/6 or BALB/c), it is possible that the adjuvant activity of PADRE plays a role.
As expected, PPD is the most promising of the 2 platforms described in this article: it not only generates high affinity memory CTLs and a strong humoral response but, in prevention models, it shows an efficacy far superior to that observed with dermal electroporation. It is important to underline that dermal electroporation has been highly optimized with considerable industrial effort and investment and it is considered the gold standard for DNA vaccination by assuring: (i) high transfection efficiency, (ii) a danger signal, and (iii) and physical needle-mediated targeting of dermal APCs. Thus, our observations that the not-yet fully optimized PPD platform can generate a protective immunity superior to the one obtained with dermavax suggests a potentially very high impact for this technology (Fig. 5) .
The promise of this platform is further elucidated in the therapeutic setting where the delivery of pcDNA3-TRP2 via PPD leads to B16 tumor regression and mice survival is roughly 50%. The observation that TRP2 vaccination using unmodified dendrimers is ineffective and that only a modest increase in survival is achieved when PADRE is mixed with the vaccine (Fig. 6 ), strongly suggest that PADRE, when it is conjugated to the dendrimers in the PPD formulation, not only exerts an adjuvant effect (30, 31) , but also can target the dendrimer and its DNA cargo to the appropriate APCs.
Considering that PADRE binds most human HLA-DR as well as monkey MHC class II (data not shown), the data presented here not only represents proof of concept of this new nanoparticle-based DNA vaccination but also suggests that PPD is a good candidate for DNA-based immunization in human diseases. 
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